VoltraPeptides like BPC-157 and retatrutide: what's known, and what's legal
Peptides sold online for muscle, healing or weight loss aren't approved medicines: no product containing BPC-157 is approved in any country [6], the FDA found no human data for TB-500 [11], and retatrutide is still an experimental drug [13]. On 29 September 2026 Saudi Arabia's Food and Drug Authority said it had caught websites and social media accounts selling unregistered peptides; selling them can bring a fine of up to SAR 5 million, five years in prison, or both [1].
Where each one stands
| Substance | Status |
|---|---|
| BPC-157 | No product approved in any country; almost no human studies [6] |
| TB-500 | No human data found by the FDA [11] |
| Retatrutide | Investigational drug in Phase 3 trials; not approved [12] [13] |
What Saudi Arabia announced
On 29 September 2026 the Saudi Food and Drug Authority (SFDA) said it had found unregistered peptide products being marketed through websites and social media accounts without the required licence [1]. It said the products were of unknown origin and had not met the rules for safe transport, storage and the drug supply chain, and that some sellers falsely presented them as tested, high quality and officially approved [1].
Selling, dispensing or holding an unregistered pharmaceutical product to trade it breaks Article 34(2) of Saudi Arabia's law on pharmaceutical establishments and preparations; penalties go up to SAR 5 million, five years in prison, or both [1]. The SFDA added that using such products without medical supervision may expose people to health risks, and that the store owners are being referred to the Public Prosecution [1]. Its statement doesn't name particular peptides.
In March 2026, Saudi Arabia's Ministry of Health, working with the SFDA, caught gym trainers in Riyadh selling weight-loss drugs, hormones and unregistered peptides, including unregistered retatrutide, which the ministry said is still in clinical studies and not yet proven safe [2]. It contacted buyers to tell them to stop using and dispose of the products and see a doctor, and asked people to report violations on 937 [2].
Elsewhere in the Gulf, the UAE's Emirates Drug Establishment warned in July 2026 that not every product marketed as a peptide is suitable or safe, according to Emarat Al Youm [3], and in August Qatar's Ministry of Public Health warned against trading and using peptides, including products labelled for research or not for human use, according to Al-Sharq [4]. We found no statement on peptides from Kuwait's Ministry of Health as of 30 September 2026.
BPC-157: almost no human evidence
A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies: 35 preclinical (animal or lab) and one clinical [5]. In its July 2026 review, the US FDA said no product containing BPC-157 is approved in any country [6]. It found no studies giving BPC-157 to people by mouth, by injection under the skin, through the nose or on the skin; only two enema studies lasting up to two weeks and one small ulcerative colitis trial reported in a meeting abstract [6]. It concluded that there is insufficient clinical safety information, and listed adverse events reported to it: injection-site reactions, shortness of breath, and darkening of the skin and gums [6].
BPC-157's US status has moved. The FDA put it on its list of compounding substances that may present significant safety risks on 29 September 2023 [7]; the nomination was later withdrawn, and by April 2026 the FDA listed it as "nominated but withdrawn" while still publishing its safety concerns [8]. FDA staff proposed not letting pharmacies compound it [6], but in July 2026 an FDA advisory committee voted 8–6, with one abstention, to recommend allowing BPC-157 for ulcerative colitis in compounding [9]. Advisory committee votes are non-binding [10], and we found no final FDA decision as of 30 September 2026.
TB-500
The FDA says it is particularly concerned that there are no human data on products containing TB-500, by any route, and it found no report of TB-500 being given to patients to treat any condition, wound healing included [11].
Retatrutide
Retatrutide is an experimental weekly injection from Eli Lilly that acts on three hormone receptors [13]. Its Phase 3 obesity trial TRIUMPH-1 finished collecting its main results on 6 April 2026 [12], and Lilly calls it "an investigational molecule that cannot be legally sold or marketed for human use" [13].
The FDA says retatrutide can't be used in compounding, isn't part of any FDA-approved drug and hasn't been found safe and effective for any condition, and that it has warned companies selling it labelled "for research purposes" or "not for human consumption" [14]. In one warning letter it said such labels don't change that the products are drugs meant for people [15].
Banned in tested sport
The World Anti-Doping Agency's 2026 list bans BPC-157 by name under S0, non-approved substances, and "Thymosin-ß4 and its derivatives e.g. TB-500" under S2 [16]. S0 covers any substance "with no current approval by any governmental regulatory health authority for human therapeutic use" [16], so an unapproved drug such as retatrutide falls under it too, though it isn't named. From 1 January 2027, the S0 definition spells out "designer drugs, peptides, substances approved only for veterinary use" [17].
If you're after weight loss or muscle
The SFDA's advice is to check that a product is registered before buying it and to buy pharmaceutical products only from authorised, reliable sources [1]. Approved weight-loss medicines exist and are prescribed by a doctor; our guide to GLP-1 medicines covers eating and keeping your muscle on them. For muscle, the evidence is for enough protein and progressive strength training: see how much protein you need.
In Voltra
Voltra doesn't sell, recommend or advise on peptides. It helps with what the evidence supports: set a calorie target and a protein target on the Eat tab (the Coach can set them for you), and log your strength sessions in Train.
Frequently asked
Are peptides legal in Saudi Arabia?
Selling, dispensing or holding an unregistered pharmaceutical product to trade it breaks Article 34(2) of Saudi Arabia's pharmaceutical law, with penalties of up to SAR 5 million, five years in prison or both, the SFDA says. It advises buying medicines only from authorised, reliable sources.
Is BPC-157 safe?
Nobody knows. The US FDA found no studies of BPC-157 in people by injection, mouth, nose or skin, says there is insufficient clinical safety information, and says no product containing it is approved in any country.
Is retatrutide approved?
No. It is an investigational drug from Eli Lilly, tested in Phase 3 trials. The FDA says it hasn't been found safe and effective for any condition, and Saudi Arabia's health ministry has seized unregistered retatrutide sold by gym trainers.
Are peptides banned in sport?
For tested athletes, yes. WADA's 2026 list bans BPC-157 and TB-500 by name, and any substance with no current approval for human therapeutic use.
Sources
- Saudi Food and Drug Authority (2026). SFDA takes action against websites and online accounts marketing unregistered peptides (news, 29 September 2026). The Arabic version is the original.
- وزارة الصحة، المملكة العربية السعودية (٢٠٢٦). الصحة تضبط مروجي أدوية غير مرخصة وتحذر من الأدوية غير المسجلة. In Arabic.
- الإمارات اليوم (٢٠٢٦). منتجات الـ «ببتايد».. وعود وهمية للعضلات وإنقاص الوزن والشباب الدائم. In Arabic. A news report quoting the Emirates Drug Establishment.
- الشرق (الدوحة) (٢٠٢٦). الصحة تحذر من تداول واستخدام «الببتايد». In Arabic. A news report on Qatar's Ministry of Public Health.
- Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 21(4):485–495. Abstract.
- U.S. Food and Drug Administration (2026). Evaluation of BPC-157-related bulk drug substances for inclusion on the 503A bulks list (briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026). Pages 25, 29, 43–47.
- U.S. Food and Drug Administration (2024). Certain bulk drug substances for use in compounding that may present significant safety risks (archived copy, content current as of 27 September 2024). BPC-157 listed 29 September 2023.
- U.S. Food and Drug Administration (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). Section: nominated but withdrawn.
- Eglovitch JS, Regulatory Focus (RAPS) (2026). FDA advisory committee backs two controversial peptides (23 July 2026). A trade news report.
- U.S. Food and Drug Administration (2026). July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. What is an advisory committee?
- U.S. Food and Drug Administration (2026). Evaluation of TB-500-related bulk drug substances (briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026). Pages 32–33.
- ClinicalTrials.gov (2026). NCT05929066 (TRIUMPH-1): retatrutide (LY3437943) once weekly in people with obesity or overweight, Phase 3. Primary completion 6 April 2026.
- Eli Lilly and Company (2026). Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (press release, 23 July 2026). Company press release.
- U.S. Food and Drug Administration (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 September 2026)
- U.S. Food and Drug Administration (2026). Warning letter to Gram Peptides, MARCS-CMS 721806 (31 March 2026)
- World Anti-Doping Agency (2026). Prohibited List 2026. S0 (page 4) and S2.3 (page 8).
- World Anti-Doping Agency (2026). Prohibited List 2027 (in force 1 January 2027). S0 (page 4).
Sources checked on 30 September 2026.
Log your food and training with Voltra. Free to download; the yearly plan starts with a 7-day free trial. Works fully in English and Arabic.
